Back to search results
Completed

Pancreatic Cancer

A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer

JBEG | {{ defaultRegistry.registryAnchorText }} NCT02734160 {{ currentLocaleObject.registryAnchorText }}

Study Purpose

The main purpose of this study is to evaluate the safety and efficacy of the study drug known as galunisertib administered in combination with the anti-programmed cell death-ligand 1 (PD-L1) antibody, durvalumab, in participants with refractory metastatic pancreatic cancer.

Completed Study

The results of this study are not yet available.

Time Commitment

The duration of your participation depends on how well your disease responds to the study treatment.

Who Participated? Tool Tip Icon

Here you can find out a bit more about the requirements for volunteers who took part in this study

Gender

Male Female

Age

18+ years
  • Participants must have metastatic pancreatic cancer, confirmed by histology or cystology. Recurrence must be documented by diagnostic biopsy.

  • Participants must have had disease progression, been resistant, or intolerant to no more than 2 prior systemic regiments for locally advanced or metastatic pancreatic cancer.

  • Participants who have received prior neoadjuvant therapy and who now have metastatic disease must have received 1 of the following treatments for their metastatic disease: FOLFIRINOX, nanoparticle albumin-bound paclitaxel/gemcitabine, TS-1 (tegafur gimeracil oteracil potassium), irinotecan liposome injection/5-fluorouracil (5FU)/Leucovorin or single-agent gemcitabine prior to entering the study

  • For some parts of the study, participants must be willing to undergo a tumor biopsy or to provide an available archival tumor sample

  • Participants must use approved contraceptive methods

  • Participants must not have moderate or severe cardiovascular disease

Where This Study Took Place Tool Tip Icon

Where This Study Took Place Tool Tip Icon

Invalid Postal Code.
Please re-enter postal code.

{{sites.getPageStartCount()}} - {{sites.getPageEndCount()}} of {{sites.totalCount}} Results

0 of {{sites.totalCount}} Results

Distance Location
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Closest Location
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Other Location(s)
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,

To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled.
This website is not optimized for your browser, as configured.